Proficio Capital Partners LLC Purchases New Stake in Incyte Co. (NASDAQ:INCY)

Proficio Capital Partners LLC purchased a new stake in shares of Incyte Co. (NASDAQ:INCYFree Report) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 51,388 shares of the biopharmaceutical company’s stock, valued at approximately $3,549,000.

Other institutional investors also recently bought and sold shares of the company. Victory Capital Management Inc. raised its holdings in shares of Incyte by 11.1% during the 4th quarter. Victory Capital Management Inc. now owns 119,358 shares of the biopharmaceutical company’s stock valued at $8,244,000 after buying an additional 11,902 shares during the period. Commerzbank Aktiengesellschaft FI purchased a new stake in shares of Incyte during the fourth quarter valued at approximately $212,000. Charles Schwab Investment Management Inc. lifted its position in shares of Incyte by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,643,067 shares of the biopharmaceutical company’s stock worth $113,487,000 after purchasing an additional 33,847 shares in the last quarter. NINE MASTS CAPITAL Ltd purchased a new position in shares of Incyte in the fourth quarter valued at $396,000. Finally, Grandfield & Dodd LLC grew its holdings in Incyte by 3.5% during the 4th quarter. Grandfield & Dodd LLC now owns 20,207 shares of the biopharmaceutical company’s stock valued at $1,396,000 after purchasing an additional 682 shares in the last quarter. 96.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

INCY has been the topic of a number of analyst reports. Citigroup dropped their target price on Incyte from $97.00 to $88.00 and set a “buy” rating on the stock in a research report on Tuesday, February 11th. JMP Securities restated a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. UBS Group initiated coverage on Incyte in a research note on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price for the company. William Blair restated an “outperform” rating on shares of Incyte in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $75.25.

View Our Latest Report on INCY

Insider Activity

In other Incyte news, EVP Sheila A. Denton sold 14,069 shares of the stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $74.07, for a total value of $1,042,090.83. Following the completion of the sale, the executive vice president now owns 25,848 shares in the company, valued at $1,914,561.36. This trade represents a 35.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Steven H. Stein sold 12,352 shares of Incyte stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $72.69, for a total value of $897,866.88. Following the transaction, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. The trade was a 15.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 27,020 shares of company stock worth $1,981,882 in the last 90 days. Corporate insiders own 17.60% of the company’s stock.

Incyte Trading Down 8.6 %

Shares of NASDAQ INCY opened at $62.01 on Tuesday. Incyte Co. has a fifty-two week low of $50.35 and a fifty-two week high of $83.95. The firm has a market capitalization of $12.00 billion, a P/E ratio of 229.68, a P/E/G ratio of 0.41 and a beta of 0.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.97 and a quick ratio of 1.94. The company’s 50 day simple moving average is $71.55 and its 200 day simple moving average is $70.31.

Incyte (NASDAQ:INCYGet Free Report) last announced its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%. On average, analysts predict that Incyte Co. will post 4.86 EPS for the current year.

About Incyte

(Free Report)

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.

Featured Stories

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCYFree Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.